COVID-19 Mar 20, 2020• By JESSICA DaMASSA, WTF HEALTH “What’s happening in COVID is those of us living with these chronic conditions are at highest risk — not to contract the disease, but highest risk for outcomes. Our unique ability to be able to see what’s happening in that population and deliver that care remotely… Read More »
FDA Approves Sarclisa (isatuximab-irfc) for Patients with Relapsed Refractory Multiple Myeloma Print this page BRIDGEWATER, N.J., March 2, 2020 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least… Read More »
The American Society for Reproductive Medicine (ASRM) has issued new recommendations regarding vaccinations for women of reproductive ages to handle female infertility, updating previous guidelines issued in 2008. The new guidelines offer the gynecologist a reminder that they can hang on their wall, according to, Dr. Samantha Pfeifer, MD, who led the study and is an associate… Read More »
All but one of the nine people being treated for the coronavirus in the UK have been discharged from hospital. They were discharged after twice testing negative for the virus, NHS England said on Saturday. Meanwhile, all 94 people who were being quarantined at Arrowe Park hospital on the Wirral have left the site. The… Read More »
From our Obsession Because China Even small changes in China have global effects. China is turning to potentially risky measures to track down more patients of a coronavirus outbreak that has killed at least 900 people. The number of infections from the new virus soared to cross 40,000 as of Sunday (Feb. 9). At least… Read More »
Print this page KENILWORTH, N.J.–(BUSINESS WIRE) January 8, 2020 –Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with… Read More »